搜尋
Aligos Therapeutics Inc
ALGS添加自選
5.490USD
+0.040+0.73%
交易中 （美東）報價延遲15分鐘
33.97M總市值
虧損本益比TTM
關於 Aligos Therapeutics Inc 公司
Aligos Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronavirus infections such as, SARS-Co-V2, SARS-CoV, MERS-CoV, and other related infections. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.
Aligos Therapeutics Inc簡介
公司代碼ALGS
公司名稱Aligos Therapeutics Inc
上市日期Oct 16, 2020
CEOBlatt (Lawrence M)
員工數量70
證券類型Ordinary Share
年結日Oct 16
公司地址One Corporate Dr., 2Nd Floor
城市SOUTH SAN FRANCISCO
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編94080
電話18004666059
網址https://www.aligos.com/
公司代碼ALGS
上市日期Oct 16, 2020
CEOBlatt (Lawrence M)
Aligos Therapeutics Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Lawrence M. Blatt, Ph.D.
Dr. Lawrence M. Blatt, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
88.42K
--
Dr. Julian A. Symons
Dr. Julian A. Symons
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
35.11K
+55.11%
Ms. Lesley Ann Calhoun
Ms. Lesley Ann Calhoun
Chief Financial Officer, Chief Operating Officer, Executive Vice President
Chief Financial Officer, Chief Operating Officer, Executive Vice President
5.22K
+30.85%
Mr. James P. (Jim) Scopa, J.D.
Mr. James P. (Jim) Scopa, J.D.
Independent Director
Independent Director
--
--
Dr. K. Peter Hirth, Ph.D.
Dr. K. Peter Hirth, Ph.D.
Independent Director
Independent Director
--
--
Ms. Carole L. Nuechterlein, J.D.
Ms. Carole L. Nuechterlein, J.D.
Independent Director
Independent Director
--
--
Dr. Bridget A. Martell, M.D.
Dr. Bridget A. Martell, M.D.
Independent Director
Independent Director
--
--
Mr. Jordyn Tarazi
Mr. Jordyn Tarazi
Vice President - Investor Relations and Corporate Communications
Vice President - Investor Relations and Corporate Communications
--
--
Dr. Heather Preston, M.D.
Dr. Heather Preston, M.D.
Independent Director
Independent Director
--
--
Ms. Margarita Chavez, J.D.
Ms. Margarita Chavez, J.D.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Lawrence M. Blatt, Ph.D.
Dr. Lawrence M. Blatt, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
88.42K
--
Dr. Julian A. Symons
Dr. Julian A. Symons
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
35.11K
+55.11%
Ms. Lesley Ann Calhoun
Ms. Lesley Ann Calhoun
Chief Financial Officer, Chief Operating Officer, Executive Vice President
Chief Financial Officer, Chief Operating Officer, Executive Vice President
5.22K
+30.85%
Mr. James P. (Jim) Scopa, J.D.
Mr. James P. (Jim) Scopa, J.D.
Independent Director
Independent Director
--
--
Dr. K. Peter Hirth, Ph.D.
Dr. K. Peter Hirth, Ph.D.
Independent Director
Independent Director
--
--
Ms. Carole L. Nuechterlein, J.D.
Ms. Carole L. Nuechterlein, J.D.
Independent Director
Independent Director
--
--
常見問題
Aligos Therapeutics Inc的前五大股東是誰？
Aligos Therapeutics Inc的前五大股東如下：Dr. Lawrence M. Blatt, Ph.D.
有多少機構持有Aligos Therapeutics Inc(ALGS)的股份？
截至2026Q1，共有108家機構持有Aligos Therapeutics Inc的股份，合計持有的股份價值約為2.82M，占公司總股份的52.29% 。與2025Q4相比，機構持股有所增加，增幅為-1521590.00。